Company intelligence / Profile preview

Miravo Healthcare

Mississauga, Ontario, Canada

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Miravo Healthcare commercializes several approved products in Canada and internationally, including Blexten (bilastine, allergy), Cambia (diclofenac for migraine), Suvexx (sumatriptan + naproxen for acute migraine), Pennsaid (diclofenac topical for osteoarthritis pain), Resultz (medical device for lice), and NeoVisc (medical device for joint pain); most are launched and promoted, with ongoing out-licensing and in-licensing activities.

Therapeutic areas: ImmunologyNeurologyDermatology
Modalities: Small moleculeMedical device
Industry: Biotech

Partnerships

Gebro Pharma (Pennsaid in Switzerland)Mentholatum Company (Resultz in US)Apotex (Pennsaid 2% US generic competition)Out-licensing/distribution partners globally for select products

Beyond the preview

Go deeper on Miravo Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Miravo Healthcare.

Explore the full profile